Fondazione EMN Italy Onlus
Quick facts
Phase 3 pipeline
- Bortezomib, Melphalan, Prednisone · Oncology
This combination regimen kills multiple myeloma cells by inhibiting the proteasome (bortezomib), damaging DNA (melphalan), and suppressing immune responses (prednisone). - Bortezomib, Melphalan, Prednisone, Thalidomide · Oncology
This combination regimen targets multiple pathways in multiple myeloma by inhibiting proteasome function, inducing DNA damage, suppressing TNF-α, and promoting cereblon-mediated protein degradation. - Cyclophosphamide, Prednisone, Lenalidomide · Oncology
This combination uses cyclophosphamide and prednisone as immunosuppressive/chemotherapy agents alongside lenalidomide, an immunomodulatory drug that enhances T-cell proliferation and has anti-angiogenic properties. - Melphalan, Prednisone, Lenalidomide · Oncology
Melphalan is an alkylating agent that interferes with DNA replication, Prednisone is a corticosteroid that suppresses the immune system, Lenalidomide is an immunomodulatory drug that affects cell growth and survival.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: